NEOADJUVANT IMMUNOTHERAPY
Clinical trials for NEOADJUVANT IMMUNOTHERAPY explained in plain language.
Never miss a new study
Get alerted when new NEOADJUVANT IMMUNOTHERAPY trials appear
Sign up with your email to follow new studies for NEOADJUVANT IMMUNOTHERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to stop liver cancer recurrence before surgery
Disease control Not yet recruitingThis study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in people with early-stage disease at high risk of recurrence. About 30 adults aged 18-75 with resectable stage IB o…
Matched conditions: NEOADJUVANT IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 08:49 UTC
-
Immunotherapy before surgery may stop merkel cell cancer spread
Disease control Not yet recruitingThis study tests whether giving the immunotherapy drug cemiplimab before surgery can prevent Merkel cell carcinoma from spreading to nearby lymph nodes. About 135 adults with early-stage (I or II) Merkel cell cancer will receive either cemiplimab or a placebo before their sentine…
Matched conditions: NEOADJUVANT IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New Chemo-Free combo aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study tests a new drug combination given before surgery for people with early-stage non-small cell lung cancer that does not have certain gene changes. The treatment uses focused radiation, an immunotherapy drug, and a targeted therapy to shrink tumors without standard chemo…
Matched conditions: NEOADJUVANT IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
Can less lung surgery after immunotherapy be just as safe?
Disease control Not yet recruitingThis study looks at people with stage II-IIIB non-small cell lung cancer whose tumors shrank after immunotherapy. It compares two surgery approaches: removing less lung tissue (to preserve lung function) versus the standard larger removal. The goal is to see if the smaller surger…
Matched conditions: NEOADJUVANT IMMUNOTHERAPY
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 11, 2026 20:37 UTC